{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:03:24Z","timestamp":1791655404430,"version":"4.3.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitreoretinal lymphoma (VRL) is a rare, high-grade B-cell lymphoma that affects immune-privileged sites and is classified as a variant of primary central nervous system lymphoma (PCNSL). The pathogenesis of VRL, including the origin of malignant B-cells, remains poorly understood. Cytokines, chemokines, and growth factors are thought to play critical roles in both the homing and autocrine proliferation of lymphomatous B-cells. In this study, we present the first longitudinal analysis of the dynamic interplay of vitreous immune mediators during intravitreal (IVT) methotrexate and dexamethasone therapy in a patient with VRL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A patient in their 70s with unilateral VRL underwent nine serial vitreous samplings over 12 weeks of IVT therapy with methotrexate (460 \u03bcg\/injection) and dexamethasone (0.4 mg\/injection). Each 0.2 mL vitreous sample was analyzed using a multiplex panel assessing 58 cytokines, chemokines, and growth factors. Vitreous levels were monitored longitudinally and correlated with clinical responses and optical coherence tomography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During therapy, key cytokines, including IL-10, IL-6, IL-16, IL-1RA, and sIL-2R, decreased progressively, with IL-10 becoming undetectable by day 22. Chemokines CXCL12 and CXCL13, involved in malignant B-cell homing, declined more slowly than IL-10, suggesting persistent microenvironmental support for tumor cells. MCP-1 remained elevated, whereas hepatocyte growth factor (HGF) was consistently high, indicating potentially aggressive behavior. Other immune mediators, including MIP-1\u03b1, MIP-1\u03b2, Mig (CXCL9), and IP-10 (CXCL10), showed variable kinetics, reflecting a dynamic interplay between the tumor and host immune response. Notably, certain cytokines previously reported in VRL cohorts, such as FGF2, IFN-\u03b3, TNF-\u03b1, and IL-17, were not elevated, highlighting patient-specific variability in the immunological profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case represents the first longitudinal characterization of vitreous immune mediators during IVT MTX\/dexamethasone therapy for VRL. Dynamic changes in soluble mediators mirrored clinical tumor regression and suggested potential biomarkers for disease activity, therapeutic response, and prognosis. Persistent chemokines, such as CXCL12 and CXCL13, may indicate the optimal treatment duration, whereas high HGF levels may identify patients with aggressive disease. These findings propose a novel framework for integrating intraocular immunomonitoring into personalized therapeutic strategies and deepen our understanding of the complex tumor\u2013immune microenvironment in vitreoretinal lymphoma. As derived from a single case, these observations are hypothesis-generating and require confirmation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1786294","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:27:19Z","timestamp":1781065639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Longitudinal analysis of local immunoregulatory mediators in a DLBCL vitreoretinal lymphoma receiving local chemotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Maria Carmela","family":"Saturno","sequence":"first","affiliation":[{"name":"Department of Sense Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Iannetta","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lambiase","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"de Smet","sequence":"additional","affiliation":[{"name":"Retina Associates, MIOS SA","place":["Lausanne, Switzerland"]},{"name":"Icahn School of Medicine, New York Eye and Ear Infirmary of Mount Sinai","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge.","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/bloodadvances.2021004212","article-title":"The molecular hallmarks of primary and secondary vitreoretinal lymphoma.","volume":"6","author":"Bonzheim","year":"2022","journal-title":"Blood Adv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma.","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000370158","article-title":"Intraocular lymphoma models.","volume":"1","author":"Aronow","year":"2015","journal-title":"Ocul Oncol Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2023.03.010","article-title":"Longitudinal analysis of ocular manifestation and interleukin during intravitreal treatment of vitreoretinal lymphoma with methotrexate.","volume":"251","author":"Gu","year":"2023","journal-title":"Am J Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e71092","DOI":"10.1002\/cam4.71092","article-title":"Exploration of the optimal treatment modality for vitreoretinal lymphoma: a PRISMA compliant meta-analysis and systematic review.","volume":"14","author":"Gao","year":"2025","journal-title":"Cancer Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2021.02.025","article-title":"Emerging insights into origin and pathobiology of primary central nervous system lymphoma.","volume":"509","author":"You","year":"2021","journal-title":"Cancer Lett."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1002\/ijc.25236","article-title":"Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells.","volume":"127","author":"Venetz","year":"2010","journal-title":"Int J Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"654543","DOI":"10.3389\/fneur.2021.654543","article-title":"CXCL13 and CXCL9 CSF levels in central nervous system lymphoma-diagnostic, therapeutic, and prognostic relevance.","volume":"12","author":"Masouris","year":"2021","journal-title":"Front Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3892\/ol.2024.14370","article-title":"Assessment and prognostic significance of a serum cytokine panel in diffuse large B\u2212cell lymphoma.","volume":"27","author":"Xie","year":"2024","journal-title":"Oncol Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1167\/iovs.11-8719","article-title":"Immune mediators in vitreous fluids from patients with vitreoretinal B-cell lymphoma.","volume":"53","author":"Usui","year":"2012","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cca.2020.12.035","article-title":"The diagnostic value of IL-10 and IL-6 level in vitreous fluid and aqueous humor for vitreoretinal lymphoma.","volume":"515","author":"Chen","year":"2021","journal-title":"Clin Chim Acta."},{"key":"B13","doi-asserted-by":"publisher","first-page":"856039","DOI":"10.3389\/fimmu.2022.856039","article-title":"IL-6 and IL-10 are associated with Gram-negative and Gram-positive bacteria infection in lymphoma.","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0138747","DOI":"10.1371\/journal.pone.0138747","article-title":"Expression of interleukin-1 and interleukin-1 receptors type 1 and type 2 in hodgkin lymphoma.","volume":"10","author":"Oelmann","year":"2015","journal-title":"PLoS One."},{"key":"B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-022-00401-4","article-title":"Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.","volume":"10","author":"Huo","year":"2022","journal-title":"Biomark Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s00277-023-05560-4","article-title":"Role and application of chemokine CXCL13 in central nervous system lymphoma.","volume":"103","author":"Li","year":"2024","journal-title":"Ann Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0161-6420(02)01737-2","article-title":"Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma.","volume":"110","author":"Chan","year":"2003","journal-title":"Ophthalmology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1309\/NUQHJ79BHWYD9TAF","article-title":"Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1.","volume":"127","author":"Smith","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1158\/1078-0432.CCR-09-0108","article-title":"CXCL13 and CXCL12 in central nervous system lymphoma patients.","volume":"15","author":"Fischer","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B20","first-page":"112","article-title":"Expression of MCP-1 and CCR2 in newly diagnosed diffuse large B-cell lymphoma and clinical significance.","volume":"32","author":"Wang","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"B21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bjh.13659","article-title":"CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.","volume":"171","author":"Takahashi","year":"2015","journal-title":"Br J Haematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.18632\/oncotarget.8203","article-title":"Molecular and clinical significance of fibroblast growth factor 2 (FGF2 \/bFGF) in malignancies of solid and hematological cancers for personalized therapies.","volume":"7","author":"Akl","year":"2016","journal-title":"Oncotarget."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.4049\/jimmunol.180.6.3789","article-title":"IFN-beta provides immuno-protection in the retina by inhibiting ICAM-1 and CXCL9 in retinal pigment epithelial cells.","volume":"180","author":"Hooks","year":"2008","journal-title":"J Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/jlb.64.3.384","article-title":"Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12.","volume":"64","author":"Kanegane","year":"1998","journal-title":"J Leukoc Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2141.2004.05197.x","article-title":"Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma.","volume":"127","author":"Kawano","year":"2004","journal-title":"Br J Haematol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1786294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:27:28Z","timestamp":1781065648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1786294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":25,"alternative-id":["10.3389\/fmed.2026.1786294"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1786294","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1786294"}}